Eli Estey

1.5k total citations · 2 hit papers
10 papers, 996 citations indexed

About

Eli Estey is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Eli Estey has authored 10 papers receiving a total of 996 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 4 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Eli Estey's work include Acute Myeloid Leukemia Research (9 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). Eli Estey is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). Eli Estey collaborates with scholars based in United States, United Kingdom and Sweden. Eli Estey's co-authors include D. Gary Gilliland, Ilene Galinsky, David Lebwohl, Wilson Grandin, Stephen D. Nimer, James D. Griffin, Donna Neuberg, Jennifer Clark, Richard M. Stone and Yanfeng Wang and has published in prestigious journals such as Blood, Nature Reviews Disease Primers and Drugs.

In The Last Decade

Eli Estey

10 papers receiving 973 citations

Hit Papers

Patients with acute myeloid leukemia and an activating mu... 2004 2026 2011 2018 2004 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412
    2004 528 citations Richard M. Stone, Daniel J. DeAngelo et al. Blood profile →
  2. Acute myeloid leukaemia
    2016 289 citations Asim Khwaja, Magnus Björkholm et al. Nature Reviews Disease Primers profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eli Estey United States 8 782 480 247 161 136 10 996
Paola Panetta Italy 14 573 0.7× 440 0.9× 162 0.7× 234 1.5× 145 1.1× 27 858
Carla Mazzone Italy 15 576 0.7× 479 1.0× 219 0.9× 191 1.2× 183 1.3× 47 951
Amer M. Zeidan United States 7 493 0.6× 378 0.8× 126 0.5× 95 0.6× 160 1.2× 21 729
Lisa Hopcroft United Kingdom 13 489 0.6× 342 0.7× 293 1.2× 48 0.3× 141 1.0× 23 814
Elisabeth Oppliger Leibundgut Switzerland 16 412 0.5× 480 1.0× 311 1.3× 72 0.4× 178 1.3× 38 897
Kara Johnson United States 15 607 0.8× 313 0.7× 472 1.9× 93 0.6× 114 0.8× 19 978
Alice Huntsman-Labed United States 7 592 0.8× 325 0.7× 214 0.9× 107 0.7× 58 0.4× 10 754
Amanda Winters United States 15 1.1k 1.4× 999 2.1× 177 0.7× 262 1.6× 250 1.8× 39 1.6k
Pauline Schneider Netherlands 18 512 0.7× 618 1.3× 93 0.4× 576 3.6× 143 1.1× 41 1.1k
P. Rae United States 6 984 1.3× 412 0.9× 679 2.7× 172 1.1× 279 2.1× 8 1.4k

Countries citing papers authored by Eli Estey

Since Specialization
Citations

This map shows the geographic impact of Eli Estey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Estey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Estey more than expected).

Fields of papers citing papers by Eli Estey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eli Estey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Estey. The network helps show where Eli Estey may publish in the future.

Co-authorship network of co-authors of Eli Estey

This figure shows the co-authorship network connecting the top 25 collaborators of Eli Estey. A scholar is included among the top collaborators of Eli Estey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eli Estey. Eli Estey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Martens, Kylee L., Shan Li, Andrew A. White, et al.. (2020). Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Leukemia Research. 89. 106298–106298. 15 indexed citations
2.
3.
Khwaja, Asim, Magnus Björkholm, Rosemary E. Gale, et al.. (2016). Acute myeloid leukaemia. Nature Reviews Disease Primers. 2(1). 289 indexed citations breakdown →
4.
Fenaux, Pierre, John F. Seymour, Valeria Santini, et al.. (2013). Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model. Leukemia Research. 38(2). 258–262. 5 indexed citations
5.
Nazha, Aziz, Carlos Bueso-Ramos, Eli Estey, et al.. (2013). The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia. Frontiers in Oncology. 3. 218–218. 17 indexed citations
6.
7.
8.
Scott, Bart L. & Eli Estey. (2008). Management of myelodysplastic syndromes: 2008 update.. PubMed. 22(12). 1344–52. 9 indexed citations
9.
Stone, Richard M., Daniel J. DeAngelo, Virginia M. Klimek, et al.. (2004). Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 105(1). 54–60. 528 indexed citations breakdown →
10.
Keating, Michael J., et al.. (1994). Clinical Experience with Fludarabine in Leukaemia. Drugs. 47(Supplement 6). 39–49. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola Panetta Breakdown of academic impact, for papers by Carla Mazzone Breakdown of academic impact, for papers by Amer M. Zeidan Breakdown of academic impact, for papers by Lisa Hopcroft Breakdown of academic impact, for papers by Elisabeth Oppliger Leibundgut Breakdown of academic impact, for papers by Kara Johnson Breakdown of academic impact, for papers by Alice Huntsman-Labed Breakdown of academic impact, for papers by Amanda Winters Breakdown of academic impact, for papers by Pauline Schneider Breakdown of academic impact, for papers by P. Rae
Rankless by CCL
2026